Anteris Technologies Files SEC Amendments to Revise CEO and CFO Certifications Across Three Prior Reports

Aakashdeep

10 November 2026 12:56 PM AEDT

Anteris Technologies Files SEC Amendments to Revise CEO and CFO Certifications Across Three Prior Reports

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Anteris Technologies Global Corp. (ASX:AVR) has disclosed that on 9 November 2026 it filed amendments with the U.S. Securities and Exchange Commission to revise officer certifications contained in its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and its Quarterly Reports on Form 10-Q for the periods ended March 31, 2026 and June 30, 2026.

Key Points

Anteris filed Amendment No. 1 on Form 10-K/A to its Annual Report for the fiscal year ended December 31, 2025.
Amendment No. 1 on Form 10-Q/A was filed for each of the quarterly periods ended March 31, 2026 and June 30, 2026.
The amendments revise certifications of the Chief Executive Officer and Chief Financial Officer to include language regarding internal control over financial reporting that was omitted from the original filings.
The amendments do not change the company's previously reported financial statements or results.

Purpose of the SEC Amendments

According to the filing, the amendments were filed solely to revise the certifications of the company's Chief Executive Officer and Chief Financial Officer, which were included as exhibits to the original filings. The specific revision adds language regarding internal control over financial reporting that was omitted from those original certifications. The filing states that the amendments do not otherwise amend or update the original filings in any other respect, and no changes have been made to the company's previously reported financial statements or results.

Scope of Filings Covered

Three separate amended filings were lodged with the SEC on 9 November 2026, covering US Central time and Australian Eastern Standard Time. These comprised one Form 10-K/A relating to the annual reporting period ended December 31, 2025, and two Forms 10-Q/A covering the quarterly periods ended March 31, 2026 and June 30, 2026 respectively. All three amendments are described in the filing as Amendment No. 1 to their respective original reports, and the company is dual-listed on the Nasdaq Global Market and the ASX under the ticker AVR.

Company Description and Authorisation

Anteris Technologies Global Corp. is described in the filing as a global healthcare company committed to designing, developing, and commercialising medical devices to restore healthy heart function, with operations based in Brisbane, Minneapolis, Geneva, and Malaga. The company's lead product is the DurAVR® Transcatheter Heart Valve, designed to treat aortic stenosis. The filing states that ADAPT® tissue, used in the DurAVR® THV, is FDA-cleared and has been used clinically for over 10 years, distributed for use in over 55,000 patients worldwide. The company disclosure was authorised for release by Wayne Paterson, Vice Chairman and Chief Executive Officer.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.